Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead

被引：193

作者：

Minard-Colin, Veronique ^{[1
]}

Brugieres, Laurence ^{[1
]}

Reiter, Alfred

Cairo, Mitchell S. ^{[11
]}

Gross, Thomas G. ^{[12
]}

Woessmann, Wilhelm ^{[7
]}

Burkhardt, Birgit ^{[8
]}

Sandlund, John T. ^{[13
,14
]}

Williams, Denise ^{[16
]}

Pillon, Marta ^{[17
]}

Horibe, Keizo ^{[20
]}

Auperin, Anne ^{[1
]}

Le Deley, Marie-Cecile ^{[1
]}

Zimmerman, Martin ^{[9
]}

Perkins, Sherrie L. ^{[15
]}

Raphael, Martine ^{[2
]}

Lamant, Laurence ^{[5
,6
]}

Klapper, Wolfram ^{[10
]}

Mussolin, Lara ^{[18
,19
]}

Poirel, Helene A. ^{[21
]}

Macintyre, Elizabeth ^{[3
,4
]}

Damm-Welk, Christine ^{[7
]}

Rosolen, Angelo ^{[17
]}

Patte, Catherine ^{[1
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Univ Paris 11, CNRS, UMR 8126, Paris, France

[3] Univ Paris Descartes Sorbonne Cite, Inst Necker Enfants Malad, Inst Natl Rech Med U1151, Paris, France

[4] Hop Necker Enfants Malad, AP HP, Paris, France

[5] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[6] Univ Toulouse 3, F-31062 Toulouse, France

[7] Univ Giessen, D-35390 Giessen, Germany

[8] Children Univ Hosp, Munster, Germany

[9] Hannover Med Sch, D-30623 Hannover, Germany

[10] Univ Kiel, Kiel, Germany

[11] New York Med Coll, Valhalla, NY 10595 USA

[12] NCI, Bethesda, MD 20892 USA

[13] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

[14] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN USA

[15] Univ Utah Hlth Sci, Salt Lake City, UT USA

[16] Cambridge Univ Hosp Fdn Trust, Cambridge, England

[17] Univ Padua, Padua, Italy

[18] Fdn Cittadella Speranza, Ist Ric Pediat, Padua, Italy

[19] Univ Padua, Padua, Italy

[20] Natl Hosp Org, Nagoya Med Ctr, Nagoya, Aichi, Japan

[21] Catholic Univ Louvain, Clin Univ St Luc, Ctr Human Genet, B-1200 Brussels, Belgium

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 27期

关键词：

LARGE-CELL LYMPHOMA; ACUTE-LYMPHOBLASTIC-LEUKEMIA; MINIMAL DISSEMINATED DISEASE; HIGH-DOSE METHOTREXATE; ADVANCED-STAGE; BURKITT-LYMPHOMA; PEDIATRIC-PATIENTS; FRENCH-SOCIETY; BONE-MARROW; MULTIAGENT CHEMOTHERAPY;

D O I：

10.1200/JCO.2014.59.5827

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse. (C) 2015 by American Society of Clinical Oncology

引用

页码：2963 / U54

页数：14

共 99 条

[21] Clinical Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric T-Cell Lymphoblastic Lymphoma [J].